secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0000950123-24-005877
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics appoints Julianne Bruno as COO effective May 23, 2024
-------------------------------------------------------------------------

- Bruno previously SVP and Head of Programs & Portfolio; led hemoglobinopathy partnership with Vertex.
- Annual salary of $460,000, target bonus 45% of base, and eligible for equity plans.
- Received one-time grant of 20,000 RSUs vesting over 4 years (25% annually).
- Employment agreement provides 6-month notice period; 12-month notice and accelerated vesting after change in control.
- Bruno holds MBA from Wharton, AB from Princeton; prior McKinsey biotech practice leader.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095012324005877/0000950123-24-005877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095012324005877/crsp-20240523.htm
  HTML page:      https://secwatch.observer/filing/0000950123-24-005877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer